Avineuro Announced Advancing Potent Small Molecule For Treatment Of Alzheimer's Disease To Clinical Development

Avineuro Pharmaceuticals, Inc.
announced today the completion of preclinical studies of AVN-101, a potent
small molecule for treatment of Alzheimer's disease. These studies
demonstrate that AVN-101 is safe and well tolerated, and that it has a
favorable pharmacokinetic profile. Based on these and other results,
Avineuro Pharmaceuticals, Inc. plans to advance AVN-101 into clinical
trials in Q1 2009. Results of the studies will be presented at the 9th
International Conference -- AD/PD 2009 -- Prague, Czech Republic, March
11-15, 2009.



About Avineuro Pharmaceuticals, Inc.:



Avineuro discovers and develops novel small molecules for unmet medical
needs in neurology and psychiatry. Avineuro emphasizes a rational approach
to drug discovery that combines modern medicinal chemistry with streamlined
pre-clinical and clinical development studies, thus allowing a fast
transition to proof-of-concept product candidates.


Avineuro Pharmaceuticals, Inc.

avineuro